A Study To Evaluate Safety And Therapeutic Activity Of RO6874281 In Combination With Pembrolizumab In Participants With Advanced Or Metastatic Melanoma
This is an open-label, multicenter, Phase Ib study to evaluate the safety and therapeutic activity of RO6874281 in combination with pembrolizumab. The study will consist of 3 parts: a safety run-in (Part I: Cohorts 1.1. and 1.2) and two expansion parts (Parts II and III). Part II will start once all participants in Cohort 1.1 have completed the observation period. Part III will start once all participants in Cohorts 1.1 and 1.2 have completed the observation period.
An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety And Therapeutic Activity Of Ro6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant (Il-2v) Targeting Fibroblast Activation Protein-Α (Fap), In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma
- ClinicalTrials.gov Identifier: NCT03875079
- Protocol Number: 19-175
- Principal Investigator: Anupam Desai
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required